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The cognitive symptoms of schizophrenia are largely resistant to current treatment and are thus a life-long
burden of the illness. Studies of cognitive symptoms have commonly focused on prefrontal cortex because
of its demonstrated importance for executive function and working memory—key components of the deficit.
The role of striatal-cortical circuitry and therefore the striatum itself has received much less attention. Here we
review longstanding evidence that the striatum and its cortical connections are critical for complex cognition
and discuss emerging evidence of the striatum’s potential involvement in cognitive symptoms. Finally, we
suggest how mouse models might test ideas about the contribution of early striatal dysfunction to the cogni-
tive symptoms of schizophrenia.The cognitive symptoms of schizophrenia present early in the
disease, and unlike positive symptoms, including hallucinations
and delusions, cognitive symptoms are largely resistant to
current treatment and therefore persist throughout life. Many
studies of cognitive symptoms have focused on the prefrontal
cortex because of its demonstrated importance for executive
function and working memory—key components of the cognitive
deficit. However, the role of striatal cortical circuitry and there-
fore the striatum itself has received much less attention than
other brain structures affected in schizophrenia, such as the
prefrontal cortex and temporal lobe. Here we review longstand-
ing evidence that supports the idea that the striatum, and its
cortical connections, are critical for complex cognitive functions,
and we discuss the emerging evidence of the striatum’s potential
involvement in generating cognitive symptoms of schizophrenia.
Finally, we provide a general outline of how mouse models might
test ideas about early striatal dysfunction’s contribution to the
cognitive symptoms of schizophrenia.
The Importance of Understanding the Cognitive
Symptoms of Schizophrenia
Schizophrenia is formally characterized by three distinct
symptom clusters: positive, negative, and cognitive. The positive
symptoms refer to hallucinations and delusions, psychotic
abnormalities in perception and reality testing. The negative
symptoms refer to social withdrawal, lack of motivation, and
abnormalities in social interaction. The cognitive symptoms refer
to inability to organize one’s life and to work sequentially and
effectively. Although positive symptoms are the most dramatic
and characteristic symptoms of schizophrenia, they are greatly
improved with antipsychotic medication, whereas the negativeand cognitive symptoms are not, and therefore, as a result, these
two symptom clusters, and especially the cognitive symptoms
that are so debilitating, have become a major focus in schizo-
phrenia research (Keefe et al., 2007). The cognitive symptoms
of schizophrenia include deficits in semantic and explicit
memory, as well as deficits in attention, working memory, and
executive function (Cirillo and Seidman, 2003; Goldman-Rakic,
1994). The cognitive deficits are not unique to schizophrenia.
But because they affect mental abilities needed for day-to-day
functioning as well as planning for the future, the severity of these
symptoms are highly predictive of a patient’s long-term prog-
nosis, more predictive than the positive symptoms (Green, 1996).
The relevance of the cognitive symptoms of schizophrenia
was already understood more than a century ago by Kraepelin,
who in 1893 divided the major psychotic illnesses into two
groups by differentiating patients with ‘‘dementia praecox,’’ or
premature dementia (later termed schizophrenia by Eugene
Bleuler), from manic depressive illness based on their disordered
thought. Kraeplin was also the first to recognize that patients
with dementia praecox share many of the behavioral abnormal-
ities observed in the dementia of patients with lesions of the
frontal lobes (Kraepelin, 1919). Patients with frontal lobe damage
and patients with schizophrenia suffer from defects in executive
function that are measured on tasks such as the Wisconsin Card
Sorting Test (WCST), the Stroop Task, the "Tower of London"
task, and the N-back test (Kolb and Whishaw, 1983) (Figure 1).
In nonhuman primates, success in executive tasks require
optimal dopamine signaling (Brozoski et al., 1979), suggesting
that cognitive dysfunction in schizophrenia involves disturbance
of the dopamine system. This is one of many indirect observa-
tions consistent with the dopamine hypothesis of schizophrenia,Neuron 65, March 11, 2010 ª2010 Elsevier Inc. 585
Wisconsin Card Sorting Task (WCST) 
Measures: Flexibility, attentional set shifting.
Subjects must sort cards by a single feature (e.g., colour) 
and then without instruction 'shift set' to sort them by a
N-Back Test 
Measures: executive control of the updating of 
information in working memory
, ,
different category (e.g., shape or number)
Stroop Tests
Measures: flexibility resistance to interference
Subjects are presented with a series of stimuli and must 
determine if the one currently presented stimulus matches 
one that has been presented one (1back), two (2-Back) 
or three (3-back) positions previously in the stream. 
Tower of London
,
In the Color Task subjects must read aloud a list of color 
names which are printed in a non matching color. In the 
Color-Word Task, the subject must name the
color of ink in which the color names are printed. 
Measures: Problem solving, strategy Planning
Subjects must move colored disks one at a time from  an 
initial arrangement to match a goal arrangement. 
Subjects are instructed to plan the sequence of moves 
before carrying them out so that they achieve the goal 
arrangement in as few moves as possible. 
Start Goal
Figure 1. Tasks Used to Measure Prefrontal-
Cortex-Dependent Cognitive Executive Function
in Humans
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Perspectivethe most enduring and continually provocative hypothesis in
psychiatric research.The Original Dopamine Hypothesis of Schizophrenia
Based on seminal experiments by Arvid Carlsson and others
studying the effects of antipsychotic medications, Jacques
Van Rossum proposed, in 1966, that ‘‘overstimulation of dopa-
mine receptors could be part of the etiology’’ of schizophrenia
(for a historical review, see Baumeister and Francis, 2002).
Today, there is no question that intervention in the dopaminergic
system is successful in treating the positive symptoms of schizo-
phrenia. All established antipsychotic medications antagonize
dopamine D2 receptors, and their clinical efficacy correlates
directly with their occupancy of D2 receptors (Seeman et al.,
1975; Creese et al., 1976). However, the clinical efficacy of any
drug does not necessarily imply that its target is involved in an
etiological mechanism, and as already stated, D2 blockade
does not ameliorate all symptoms. But independent of antipsy-
chotic actions, there is evidence (to be described below) that
dopamine dysfunction could be involved in the pathogenesis
of the disease.
The original dopamine hypothesis did not attempt to distin-
guish between the three major dopaminergic pathways that
were identified using the Falck-Hillarp method: the mesostriatal,
the mesolimbic, and the mesocortical (Moore and Bloom, 1978)
(Figure 2). As a result, the original version of the hypothesis
viewed schizophrenia as a general dopamine hyperfunction
syndrome (Figure 1B).A Reconceptualization of the Dopamine Hypothesis
of Schizophrenia
Consistent with the potential importance of the frontal lobe first
proposed by Kraepelin, the majority of brain imaging studies of
patients with schizophrenia using both MRI and PET suggest586 Neuron 65, March 11, 2010 ª2010 Elsevier Inc.that hypofunction of the prefrontal cortex
contributes to the cognitive symptoms (Buchs-
baum et al., 1982; Farkas et al., 1984; Ingvar
and Franze´n, 1974a, 1974b; for review, see Lid-
dle et al., 1992; Ragland et al., 2007). Functional
imaging studies (fMRI) also document a further
hypofrontality in schizophrenia. During the Wis-
consin Card Sorting Test (Weinberger et al.,
1986), patients with schizophrenia show
a decrease in regional cerebral blood flow in
the frontal cortex compared to healthy controls.
These alterations in prefrontal activation have
now been demonstrated during a variety of
tasks for executive function. It is thought that hy-
poactivation of the dorsolateral prefrontal
cortex may be accompanied by compensatory
hyperactivation of directly adjacent regions, re-flecting a disturbance in the ability to engage the functional
networks subserving executive functions (Barch, 2005; Glahn
et al., 2005; Ragland et al., 2007).
There is no unequivocal evidence for a cortical dopamine
hypofunction in schizophrenia; the relationship between meta-
bolic function and dopaminergic activity is as yet indirect and
conjectured. However, there are several lines of evidence that
suggest that cortical dopamine hypofunction relates to the
cortical functions affected in patients with schizophrenia. Here
we describe six such independent lines of evidence, which
provide indirect support for the hypothesis that the metabolic
hypofunction of the prefrontal cortex observed by MRI might
involve dopamine dysregulation. (1) In animal studies, pioneered
by Pat Goldman-Rakic, dopamine signaling was identified as
important for cognition mediated by the prefrontal cortex. Deple-
tion of dopamine in the prefrontal cortex impairs working
memory in nonhuman primates (Brozoski et al., 1979), as does
blockade of dopamine D1 receptors in the PFC (Vijayraghavan
et al., 2007; Williams and Goldman-Rakic, 1995). (2) Genetic
studies support the idea that dopamine levels in the prefrontal
cortex affect cognitive function also in humans. A common
polymorphism in one of the enzymes that break down dopamine,
the gene encoding catechol-O-methyl transferase (COMT),
results in altered activity of the enzyme and presumably in the
level of dopamine available at the synapse. In healthy subjects,
the polymorphism modulates performance in the tests of
working memory and executive function that are significantly
affected in patients with schizophrenia (Bruder et al., 2005;
Egan et al., 2001). In fact, a meta-analysis of such studies,
including 12 published reports, concluded that there is a signifi-
cant effect of thisCOMT genotype on executive function, specif-
ically performance in the Wisconsin Card Sorting task, in healthy
individuals (Barnett et al., 2007). (3) In patients with schizo-
phrenia, a decrease in the immunoreactivity for both tyrosine
hydroxylase, the dopamine synthetic enzyme, and for the
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Figure 2. The Dopamine Hypothesis of Schizophrenia
(A) Organization of the nigrostriatal and mesocortical midbrain dopaminergic projections. The dopaminergic midbrain neurons topographically project to the
striatum but with an inverse dorsal-to-ventral organization. The mesocortical projections arise from the dorsal and medial dopamine cells.
(B) The original dopamine hypothesis of schizophrenia. The original dopamine hypothesis proposed that a global hyperactivity of the dopaminergic projections in
the brain may lead to the symptoms of schizophrenia.
(C) The revised dopamine hypothesis of schizophrenia. The revised dopamine hypothesis proposed that a hyperactive nigrostriatal dopaminergic projection
leads to positive symptoms but a hypoactive mesocortical projection is responsible for cognitive and negative symptoms.
(D) Results of brain imaging studies in schizophrenia. Brain imaging studies show that an increase in amphetamine-induced dopamine release in the striatum is
highest in the associative striatum. Moreover, the density and occupancy of striatal D2 receptors is increased in drug-free or drug-naive patients.
PFC, prefrontal cortex; dSTR, dorsal striatum; vSTR, ventral striatum; VTA, ventral tegmental area; SNc, substantia nigra pars compacta; SNr, substantia nigra
pars reticulata; D2R, dopamine D2 receptor.
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prefrontal cortex in the brains of patients with schizophrenia at
post mortem. This finding still awaits replication, however. (4)
In the cerebral spinal fluid of patients with schizophrenia, the
basal concentration of the dopamine metabolite homovanilic
acid correlates with the regional cerebral blood flow induced
by mental activity in the PFC (Weinberger et al., 1988; Kahn
et al., 1994). This suggests that in patients the level of prefrontal
dopamine release could predict prefrontal function (Weinberger
et al., 1988; see also Elsworth et al., 1987). Future imaging
studies that directly measure dopamine release in the cortex
are needed to further support this idea. (5) An increase in D1
receptor density has been found in the prefrontal cortex of
patients with schizophrenia using [11C]NNC as a D1-specific
PET ligand. This increase in receptor availability, which was
not observed using the earlier tracer [11C]SCH 23390 (Okubo
et al., 1997), correlates with deficits in the N-back task (Abi-
Dargham et al., 2002) and could be a compensation for the
hypoactive cortical dopaminergic projections. (6) A PET study
also using the tracer [11C]NNC showed that the COMT genotype
presumed to enhance dopamine metabolism predicts cortical-
limbic D1 receptor availability (Slifstein et al., 2008).
To reconcile the more recent evidence for dopamine hypoac-
tivity in the frontal cortex with the original hypothesis of a general
hyperdopaminergia syndrome, Weinberger and Davis proposed
a variant of the original dopamine hypothesis of schizophrenia,according to which the three major dopaminergic pathways
are not affected in similar ways in the disease. They proposed
that only the mesostriatal and mesolimbic pathways became
hyperactive and that these mediate the positive symptoms of
schizophrenia. They further suggested that the hyperactivity in
these two pathways is secondary to a hypofunction of the
prefrontal dopamine system that is responsible for the cognitive
deficits (Davis et al., 1991; Weinberger, 1987) (Figure 2C).
Although this model for the pathogenesis of schizophrenia has
been supported by animal models, there is as yet no direct
evidence derived from studies with patients. There are in fact
alternate and equally valid reasons to suggest that if dopami-
nergic dysfunction is causative in the pathogenesis of schizo-
phrenia the deficits may occur in the opposite order. We here
discuss the possibility that the striatum may have a primary
role in the pathogenesis of schizophrenia and that the striatum
plays a critical role in initiating the cognitive deficits. We present
evidence for a dopamine hyperfunction in the striatum of patients
with schizophrenia and show how this hyperfunction might
specifically contribute to the cognitive deficits of schizophrenia.
ADopaminergic Hyperfunction in the Striatum asCausal
in the Cognitive Deficits of Schizophrenia
The idea of hyperactive subcortical dopamine in schizophrenia
was originally based on the efficacy of antipsychotic medication,
but this idea has now been supported by a number of importantNeuron 65, March 11, 2010 ª2010 Elsevier Inc. 587
Neuron
Perspectivefindings, which converge on evidence for both an increase in
striatal dopamine and an increase in striatal dopamine receptors.
(Figure 2D). Evidence for increased dopamine release in the
striatum came from several sources. For example, some, though
not all, post mortem studies have detected an increase in the
level of dopamine in the striatum or an increase, even in unmed-
icated patients, in the levels of the dopamine metabolite HVA
(for a review, see Davis et al., 1991). This is consistent with the
numerous findings of an increase in striatal uptake of dopamine
in patients with schizophrenia, as determined by an increase in
the uptake of Fluoro-Dopa, by the dopamine-synthesizing
enzyme L-amino acid decarboxylase (Frankle, 2007; Hietala
et al., 1999; Hietala et al., 1995; Lindstro¨m et al., 1999; Meyer-
Lindenberg et al., 2002; Reith et al., 1994). Similarly, PET imaging
has also found that in patients with schizophrenia, there is an
increase in the striatum of amphetamine-induced displacement
of D2 receptor binding, consistent with increased dopamine
release (Abi-Dargham et al., 1998; Breier et al., 1997; Laruelle
et al., 1996).
These alterations in dopamine availability are paralleled by
changes in striatal dopamine receptors. First observed by Cross
et al. (1981) and then by others (for a review, see Davis et al.,
1991), an upregulation of striatal D2 receptors was discovered
in post mortem studies of patients who were drug-free. Similarly,
an increase in the density and occupancy of D2 receptors in the
striatum has been found in PET imaging (Abi-Dargham et al.,
2000; Seeman and Kapur, 2000; Wong et al., 1986; Laruelle,
1998). Although there has been inconsistency in these findings,
the inconsistency seems to be related to the functional proper-
ties of the different ligands that have been used. For example,
M-spiperone is more lipid soluble and more readily penetrates
cell membranes to reach internalized receptors than do the ben-
zamides that generally are water-soluble. These different classes
of ligands may also differ in their binding to monomeric versus
dimeric receptors (Seeman and Kapur, 2000). Moreover,
elevated occupancy of D2 receptors was found to be predictive
for a good treatment response of positive symptoms with anti-
psychotic drugs (Abi-Dargham et al., 2000). Although antipsy-
chotic medications increase the density of D2 receptors in the
striatum, thereby complicating the interpretations of the PET
imaging studies, a mild (12%) but highly significant elevation in
D2 receptor binding potential has also been observed in drug-
free and drug-naive patients (see meta-analysis: Laruelle, 1998).
An increase in D2 receptor binding potential does not,
however, necessarily imply an increase in the number of recep-
tors—it could also be due to an increase in the affinity of the
receptors (Seeman et al., 2006). To clarify this issue, studies
using D2 receptor ligands that preferentially bind to D2 receptors
in the high-affinity state are needed. In addition, there is a need to
determine whether the binding potential of D2 receptors is
already high in patients in the prodromal phase of the disease,
and during remission, or whether the phenotype fluctuates with
the phase of the illness, like the observed increase in amphet-
amine-induced dopamine. This would have important implica-
tions for the role of striatal D2 receptor binding in the etiology
of the disease.
With the improved resolution of PET imaging, Kegeles et al.
(2006) have been able to determine that the increase in amphet-588 Neuron 65, March 11, 2010 ª2010 Elsevier Inc.amine-induced dopamine secretion in patients with schizo-
phrenia is most pronounced in the dorsal or associative striatum,
the region also known as the head of the caudate nucleus. These
findings were surprising because animal models had suggested
that antipsychotic medication improves positive symptoms by
acting on the ventral striatum, the nucleus accumbens, rather
than the dorsal striatum, the caudate nucleus.
To date there are no ways for determining whether patients
with schizophrenia have excess D2 receptors during develop-
ment. But, if striatal dopaminergic hyperactivity is a causative
event in the disease process, then variants in genes coding for
components of dopamine signaling may be associated with
schizophrenia. Indeed, genetic studies have identified associa-
tions between variations in genes involved in dopamine signaling
and schizophrenia (Allen et al., 2008; Talkowski et al., 2008). The
continually updated meta-analyses of published schizophrenia
association studies, which currently include over 1400 studies,
continues to put the D2 receptor gene (DRD2) in the top ten
‘‘most strongly associated genes’’ (Allen et al., 2008). Of the
six individual SNPs in the D2 receptor gene subjected to the
meta-analysis, rs2677 (C957T) has the highest odds ratio of
1.37. This SNP does not affect the amino acid sequence of the
protein, but the C allele increases mRNA stability (Duan et al.,
2003) and has now been associated with schizophrenia in five
independent studies (Betcheva et al., 2009; Ha¨nninen et al.,
2006; Hoenicka et al., 2006; Lawford et al., 2005; Monakhov
et al., 2008). There are also two studies that did not find a signif-
icant association (Gupta et al., 2009; Sanders et al., 2008). In
healthy subjects, the C allele is negatively associated with cogni-
tive performance in the Wisconsin Card Sorting Test, linking D2
receptor function with cognition (Rodriguez-Jimenez et al.,
2006). Moreover, this allele interacts with the Val158Met poly-
morphism in the COMT gene in the six-word serial position
task, a test of working memory (Xu et al., 2007). While genetic
data do not support a role for any individual SNP as a significant
causative agent in schizophrenia, these data may imply that
genetic variation in the D2 receptor could contribute to the
disease and therefore warrant continued investigation. In further
support of a genetic component to D2 receptor upregulation,
unaffected monozygotic co-twins of patients with schizophrenia
show increased D2-receptor density in the caudate (Hirvonen
et al., 2005).
In summary, considerable evidence has accumulated for
a specific hyperdopaminergic state in the striatum of patients
with schizophrenia. Because the striatum is involved in aspects
of cognition and, as we discuss in the next section, the prefrontal
cortex and the striatum are anatomically interconnected, it raises
the interesting possibility that the striatum may be involved
directly in cognitive functions traditionally thought of as strictly
mediated by the prefrontal cortex. To examine this possibility
further, we review the evidence for the direct role of the striatum
in cognitive domains related to the deficits in schizophrenia.
The Striatum Has an Important Role in Cognition
The striatum, which is made up of the caudate and the putamen,
is the input component of the basal ganglia, a group of subcor-
tical nuclei that traditionally has been associated with the control
of motor movement. The striatum receives its inputs from the
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main output nuclei of the basal ganglia are the globus pallidus,
the subthalamic nucleus, the substantia nigra, and the ventral
tegmental area. These output structures mainly project to the
thalamus, the principal target of the basal ganglia. The thalamus
projects back to the cortex, thereby completing a loop that
involves the cortex, the striatum, and the thalamus (Alexander
et al., 1986). The main reason that the focus of study for the stria-
tum has been on its role in motor control is due to the established
importance of the striatum in the pathophysiology of Parkinson
and Huntington disorders, two neurodegenerative diseases
that affect motor control. The striatum is recruited for the refine-
ment of motor actions with the procedural learning of motor
habits. As a result, after extensive numbers of trials, performance
becomes insensitive to changes in the expected reward values
(Graybiel, 2005). Patients with schizophrenia show subtle defi-
cits in these types of behaviors, suggesting an impairment in
striatal function (Horan et al., 2008; Siegert et al., 2008). This
impairment is mild, however, compared to the deficits observed
in Huntington and Parkinson disorders, whose phenotypes are
comparable to those produced in animal models by extensive
lesions of the striatum.
Work in monkeys and rats beginning in the 1960s by Steven
Chorover, Haldor Rosvold, and others showed that lesions in
the dorsal striatum not only affect procedural learning but also
result in cognitive deficiencies similar to those produced by
prefrontal lesions (Battig et al., 1960; Chorover and Gross,
1963). Detailed anatomical tracing studies revealed that within
the corticostriatal pathways there are two types of projections
from the prefrontal cortex to the dorsal (associative) striatum:
focal, circumscribed projections and diffuse, widespread projec-
tions (Eblen and Graybiel, 1995). The focal projections to the
associative striatum (the head of the caudate) include some
areas of convergence between terminal fields from different
functional regions of the prefrontal cortex, such striatal nodes
may therefore be critical for integrating information encoded in
the cortex (Calzavara et al., 2007; Graybiel, 1998; Reep et al.,
2003). Consistent with this idea, Ann Graybiel has found that
information derived from the cortex is transformed in the stria-
tum, where representations of motor and cognitive action
sequences can be integrated and developed into more complex
units for implementing more efficient behavioral responses
(Graybiel, 1998). In vivo recordings reveal dramatic learning-
related changes in striatal neuronal activity as animals learn
procedural tasks requiring conditional associations (Barnes
et al., 2005; Jog et al., 1999). Taken together, these results,
and those obtained with in vivo imaging in nonhuman primates
(Levy et al., 1997) and human subjects provide strong evidence
that, in addition to modulating motor control and motor learning,
the striatum plays an important role in the formation of more
complex behaviors, including decision making and executive
function (Graybiel, 2008).
In retrospect, this view is not surprising. As we have seen, the
striatum and cortex are anatomically and functionally linked
by means of several parallel frontostriatal associative loops
(Alexander et al., 1986). In primates, the ‘‘associative loop’’
projects from the dorsolateral prefrontal cortex directly to the
associative component of the dorsal striatum (the head of thecaudate nucleus). Consequently, lesions of either the prefrontal
cortex or the dorsal striatum impair working memory (Battig
et al., 1960; Divac et al., 1967). Additional evidence for a function
of the striatum in working memory comes from physiological
studies. Neurons that show increased activity during the delay
period of a working memory task may code for the actual memory
or associated attentional or motivational information. These
‘‘memory cells,’’ originally identified in the prefrontal cortex by
Joaquin Fuster (Fuster, 1973), have also been found in the
caudate nucleus and other areas of the cortex (Hikosaka et al.,
1989). In rodents, the homologous ‘‘associative loop’’ includes
the medial prefrontal cortex and the dorsomedial striatum (the
medial caudate putamen). Lesioning this region of the striatum
affects spatial working memory (Mair et al., 2002; Voorn et al.,
2004) in the same way that lesions of the prefrontal cortex do.
Lesions of the striatum or its associative loops also affect various
attentional processes. In the Five-Choice Serial Reaction Time
Task, which measures attention in rodents, lesions of either the
dorsomedial prefrontal cortex or the medial caudate putamen
reduce response accuracy and increase premature and persev-
erative responding, implicating the striatum in attention and
cognitive control (Chudasama and Robbins, 2006). A function
of the striatum in attentional processes and cognitive control is
further suggested in humans because attentional set shifting
measured within the Wisconsin Card Sorting Task activates the
caudate nucleus in healthy human subjects (Rogers et al., 2000).
These findings suggest that the prefrontal cortex and the stria-
tum function in concert to mediate working memory and other
executive functions. The finding that the cognitive deficits in
schizophrenia may arise not simply from alterations in the
prefrontal cortex but also from a deficit in the functioning of the
striatum places the nature of the cognitive symptom in a new
light. In this regard it is interesting that the increase in amphet-
amine-induced dopamine secretion in patients with schizo-
phrenia is most pronounced in the associative striatum (Kegeles
et al., 2006), the area of the striatum that receives direct input
from the dorsolateral prefrontal cortex. Therefore, increased
dopamine release in the caudate may have a direct modulatory
effect on the efficacy of the corticostriatal synapse in the asso-
ciative striatum, potentially affecting cognitive processes such
as working memory or attentional-set shifting.
If indeed the corticostriatal pathway is critical in the generation
of cognitive symptoms of schizophrenia, it may be that compo-
nents of the loop are disabled in a particular etiological
sequence. A primary defect in the cortex has been proposed,
but direct evidence is lacking. It may therefore be interesting to
investigate the possibility that the striatum is the primary site of
dysfunction. This idea is an elaboration of the previous sugges-
tion that the striatum and associated basal ganglia are cognitive
pattern generators working in concert with the prefrontal cortex
to allow new cognitive patterns to form and that a deficit in this
striatum-based function may be a core defect in schizophrenia
(Graybiel, 1997). The hypothesis that a primary defect originates
in the striatum rather than the cortex, does not imply that the
striatal deficit is necessarily more profound than the defect in
the cortex. As we have mentioned, the cognitive behaviors that
are sensitive to striatal lesions, such as habit learning and implicit
memory, are less affected in schizophrenia than executiveNeuron 65, March 11, 2010 ª2010 Elsevier Inc. 589
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modulation of dopamine.
Testing the Specific Hypothesis that Striatal
Dysfunction Can Result in Cognitive Deficits Related
to Those Observed in Schizophrenia: The Use of Mouse
Models
The finding that hypodopaminergic function in the cortex and
hyperdopaminergic function in the striatum coexist in patients
with schizophrenia poses a number of questions. Does a single
common primary etiologic factor drive both dopaminergic
dysfunctions? Or does one perturbation drive the other? For
example, the alteration in the prefrontal cortex may precede
that of the striatum, or the alteration in the striatum may precede
that of the cortex. Of these three possibilities, only the second
has been formally proposed (Davis et al., 1991; Weinberger,
1987); we believe it is also important to investigate the other
two possibilities.
PET studies that combined measurement of regional cerebral
blood flow in the prefrontal cortex and F-Dopa uptake in the
striatum have found that prefrontal hypofunction correlates
with increased F-Dopa uptake in the striatum, suggesting that
both are functionally linked (Meyer-Lindenberg et al., 2002).
While PET studies are powerful in detecting differences in patient
populations, they do not establish causality and therefore cannot
be used to identify the origins of these dysfunctions. It may be
highly informative of the etiology of schizophrenia if we could
identify any sequential events that could be predicted to unfold
into schizophrenia. Some insights into the question could
come from studying prodromal patients. Cognitive deficits
begin to emerge in the prodromal period years before the full
onset of the disease in the patient. The early emergence of
cognitive symptoms has given rise to the idea that the prefrontal
abnormality may occur earlier than the other symptom clusters.
However, as we have seen, because the preservation of the
corticostriatal synapses is essential for prefrontal cognitive
functions, it may be impossible to use symptomatology to isolate
the origin of the pathology. Evidence supporting an early pertur-
bation has been found in both the prefrontal cortex and the
striatum. MRI has identified a reduction in frontal gray matter
volume in patients at risk for schizophrenia (Borgwardt et al.,
2007). As expected, this reduction is milder than that observed
in schizophrenic patients. Evidence for early hyperactivity of
the striatal dopamine system comes from a recent imaging study
that found that the uptake of F-Dopa is already increased in the
striatum of prodromal patients (Howes et al., 2009). On a behav-
ioral level, subtle abnormalities in motor as well as cognitive and
emotional development have been observed in children who
later develop schizophrenia (Isohanni et al., 2005; Mittal et al.,
2008; Walker et al., 1994), pointing to an early involvement of
both structures in the disease.
One useful and direct way for exploring causal mechanisms in
the pathophysiology of disease comes from animal models.
These can prove specifically useful here because they allow
perturbations that assist the investigation of the mechanisms
by which schizophrenia might possibly develop (Kellendonk
et al., 2009). In rats, dopamine depletion induced in the prefrontal
cortex by 6-OHDA increases subcortical dopamine turnover and590 Neuron 65, March 11, 2010 ª2010 Elsevier Inc.dopamine D2 receptor numbers (Pycock et al., 1980). Similar
observations have been made in primates (Roberts et al.,
1994), suggesting that prefrontal dopaminergic hypofunction
can indeed induce a hyperactive subcortical dopamine system.
However, studies with genetically modified mice have recently
presented evidence that modulation in the opposite direction is
also possible.
To address the causal relationship between striatal dopamine
dysfunction and cognition and to test the specific hypothesis
that striatal D2R hyperactivity can result in the cognitive deficits
observed in schizophrenia, Kellendonk et al. generated a genet-
ically modified mouse that modeled the observed increase in
striatal D2 receptor availability, one of the specific in vivo findings
of striatal dysfunction in schizophrenia (Kellendonk et al., 2006).
In this transgenic mouse, the expression of dopamine D2
receptors was selectively increased in the striatum, including
the caudate putamen, nucleus accumbens, and olfactory
tubercle. To obtain temporal control of transgene expression,
the mice were created using the bi-transgenic tetracycline-
sensitive expression system (Mayford et al., 1996). Striatal D2
overexpressing mice show an impairment in prefrontal-depen-
dent cognitive tasks that are associated with schizophrenia as
well as a decrease in dopamine turnover and an increase in D1
receptor activation in the prefrontal cortex (Bach et al., 2008;
Kellendonk et al., 2006). These results suggest that a selective
and primary increase in dopamine signaling restricted to the
striatum can result in deficits in both the cognitive behaviors
affected in schizophrenia and in the perturbation of the prefrontal
cortical dopamine system. Most interestingly, the cognitive defi-
cits persisted long after expression of the transgene had been
switched off. In fact, expression during development was suffi-
cient to cause cognitive deficits in adulthood.
These findings suggest two important new ideas. First,
a hyperfunctioning of the mesostriatal pathway could be an early
event in the etiology of the disease, but this hyperfunction gives
rise to compensatory changes in the prefrontal cortex that are
induced during development and maintained even after treating
the mesostriatal hyperactivity. Second, the reason D2 receptor
blockade has minimal, if any, beneficial effects on the cognitive
symptoms of schizophrenia is because antipsychotic medica-
tions are given too late, long after irreversible compensatory
changes have taken place.
How the increase in developmental D2 receptor expression
produces these phenotypes may therefore be highly informative
for the possible pathophysiological steps in the development of
the disorder. We will now discuss, in turn, how altered subcor-
tical dopamine may impact the functioning of both the striatum
and the prefrontal cortex.
The Possible Consequences of Altered Subcortical
Dopamine on Striatal Function
Several lines of evidence suggest that alterations in the subcor-
tical dopamine system affect the global functioning of the
striatum, producing both metabolic and structural changes.
Decreased metabolic activity in the basal ganglia and the stria-
tum (caudate nucleus) has been consistently found by PET
imaging studies in unmedicated patients (for review, see Buchs-
baum and Hazlett, 1998). In contrast, in patients treated with D2
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Figure 3. Three Potential Cellular
Mechanisms by which Increased Striatal
Dopamine Transmission via D2 Receptors
Could Affect Striatal Function in Patients
with Schizophrenia
(A) Heterosynaptic inhibition of corticostriatal termi-
nals. It has been shown that activation of D2 recep-
tors at the presynaptic terminal of the incoming
cortical projections inhibits corticostriatal gluta-
mate release. Heterosynaptic inhibition is selective
for the least active terminals, thereby filtering out
less active inputs (Bamford et al., 2004). Because
PET imaging does not have the resolution to deter-
mine which exact cells contribute to the elevated
binding potential of D2 receptors in the striatum,
D2 receptors could be upregulated in the
corticostriatal terminals. This in combination with
increased dopamine release may lead to a hyperef-
fective heterosynaptic inhibition that may prevent
the transmission of important cognitive information
from the cortex to the striatum.
(B) Inhibition of medium spiny neurons of the direct
pathway. Both D1 and D2 receptors are present on
medium spiny neurons, which represent 95% of striatal neurons and are the main output neurons of the striatum. D1 receptors are preferentially present on medium
spiny neurons that project directly to the substantia nigra pars reticularis and the internal segment of the globus pallidus. D1 receptor activation enhances excit-
ability of these cells. In contrast, D2 receptors are preferentially expressed on medium spiny neurons that project indirectly to the substantia nigra pars reticularis
and the internal segment of the globus pallidus. D2 receptor activation reduces excitability of these cells (Surmeier et al., 2007). Upregulation of D2 receptors may
therefore affect the balance between direct and indirect pathways and alter the striatal output of the incoming cortical information.
(C) Global inhibition of medium spiny neurons. Activation of D2 receptors on the cholinergic interneurons diminishes acetylcholine release from these cells. The
released acetylcholine affects glutamatergic and dopaminergic terminals. Acetylcholine generally enhances the glutamatergic excitation of medium spiny neurons
(Surmeier et al., 2007). Increased activation of D2 receptors on cholinergic interneurons may therefore globally reduce the excitability of the striatum. Although the
mechanism for the reduced metabolic activity observed in patients with schizophrenia is unknown, reduced cholinergic activity could be a contributing factor.
MSN, medium spiny neuron; ChAT, choline-acetyl-transferase as a marker for cholinergic interneurons; GLU, glutamate; DA, dopamine.
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Perspectivereceptor antagonists, there is an increase in striatal glucose
metabolism (Buchsbaum and Hazlett, 1998; Buchsbaum et al.,
1992; Shihabuddin et al., 1998). These two findings suggest
that D2 receptor activity negatively controls striatal metabolic
rate (see Figure 3, which discusses how overstimulation of stria-
tal D2 receptor alters physiology on the cellular level [Bamford
et al., 2004; Surmeier et al., 2007]). Data from mice that selec-
tively overexpress D2 receptors in the striatum support this
idea. D2 transgenic mice show decreased glucose metabolism
in the striatum, phenocopying the finding in unmedicated
patients (Kellendonk et al., 2006). Switching off the additional
transgenic receptor expression in the adult animal returned
glucose metabolism to normal levels, suggesting that the
changes in metabolism were due to concurrent D2 receptor
activity and not due to a developmental compensatory change.
Chronic alterations in dopamine signaling and neuronal
metabolism may lead to structural changes. In most structural
MRI studies of patients with schizophrenia, there is an increase
in striatal volume (Shenton et al., 2001). These increases appear
to be a consequence of medication, because never-medicated
patients have smaller caudate nucleus (Keshavan et al., 1998;
Shihabuddin et al., 1998), and longitundinal studies have found
that first-episode patients that are treated with neuroleptics
show increases in striatal volumes within 12–18 month (Chakos
et al., 1994; Keshavan et al., 1994). We have made similar obser-
vations in D2 receptor overexpressing mice, which, like unmed-
icated patients, show decreased striatal volume (unpublished
data). This is consistent with the observation that, when rats
are treated chronically with the D2 blocker haloperidol, striatal
volume and the area of neuronal terminals increase whereassynaptic density decreases (Andreassen et al., 2001; Roberts
et al., 1995).
If a reduction in striatal volume is indeed an early event in the
development of the disease, or an underlying risk trait, then it
may be highly valuable to measure striatal volume in individuals
identified to be in the prodromal phase of the disease. It has
already been shown that young offspring of patients with schizo-
phrenia show reduced striatal volumes compared to young
people with no family history of mental illness (Rajarethinam
et al., 2007). This finding suggests that reduced striatal volume
is a genetic risk factor or perhaps even an early marker, since
a significant proportion of the at-risk group are expected to
develop schizophrenia. A replication of this study would also
add weight to the hypothesis of early involvement of the striatum.
More importantly, longitudinal studies of individuals with high
genetic risk from an even earlier age could determine when
during development the differences in striatal volume become
apparent (Rajarethinam et al., 2007).
How Can Striatal D2 Receptors Affect the Functioning
of the Prefrontal Cortex?
There are at least three possible ways by which altered dopa-
mine signaling in the striatum could lead to prefrontal-dependent
cognitive deficits. First, dopamine signaling may disrupt or alter
the cognitive information that is coming in from the cortex. As
discussed, the striatum and cortex are anatomically and func-
tionally linked via several parallel frontostriatal loops, and in addi-
tion, nodes of convergence exist to which different cortical areas
project (Calzavara et al., 2007; Eblen and Graybiel, 1995; Reep
et al., 2003). One such node is located in the associativeNeuron 65, March 11, 2010 ª2010 Elsevier Inc. 591
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Figure 4. Mechanisms on the Circuit Level
by which Increased Striatal Dopamine
Transmission via D2 Receptors Could Lead
to Cognitive Deficits
(A) Striatal disruption. The striatum and cortex are
anatomically and functionally linked via several
parallel frontostriatal loops. Neuronal information
encoding working memory and executive function
may be altered by increased D2 receptor signaling
at the level of the medium spiny neuron in the asso-
ciative striatum, which is one synapse down-
stream of the dorsolateral prefrontal cortex.
(B) Striatal modulation of prefrontal function via
the dopaminergic system. The striatum harbors
the main input to the dopaminergic neurons of the
ventral tegmental area (VTA) and substantia nigra
(SN). By modulating the activity of neurons in the
VTA, it may modulate the dopaminergic input of
the prefrontal cortex. In mice with upregulated
D2 receptors in the striatum, prefrontal dopamine
turnover is decreased and D1 receptor activation
increased. Since optimal D1 receptor activation
in the prefrontal cortex is crucial for working
memory, this could be a mechanism by which
striatal D2 receptor overactivation may affect
prefrontal function.
(C) Striatal modulation of cortical function via the thalamus. The striatum projects back to the prefrontal cortex via the thalamus and may thereby modulate activity
in the prefrontal cortex (for simplicity only the direct pathway via the substantia nigra reticularis is drawn). These mechanisms on the circuit level could already
arise during development. In mice, selective upregulation of D2 receptors in the striatum during development leads to prefrontal-dependent cognitive deficits that
cannot be reversed by switching off the additional receptors in the adult animal. This suggests that early upregulation of D2 receptors during development leads to
compensatory changes potentially in the discussed circuits that cannot be easily reversed in the adult animal.
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Perspectivestriatum, which is where the increase in amphetamine-induced
dopamine release has been observed in patients with schizo-
phrenia. The associative striatum receives input from the dorso-
lateral prefrontal cortex and the orbitofrontal cortex (Eblen and
Graybiel, 1995; Haber et al., 2006). Increased D2 receptor
signaling at the level of the medium spiny neuron in the associa-
tive striatum may therefore disturb the integration of neuronal
information coming from different areas of the prefrontal cortex
(Figure 4A).
Second, the striatum is the main structure projecting to the
dopaminergic midbrain neurons in the ventral tegmental area
(Frankle et al., 2006). Increased signaling through striatal D2
receptors may regulate the activity of the dopaminergic neurons,
including those that project to the cortex, thereby affecting
dopamine release in the prefrontal cortex (Figure 4B). Third,
altered activity in the striatum could indirectly change cortical
functioning via the thalamus, which is part of the parallel cortico-
striatal loops (Figure 4C).
The data from these genetically modified mice suggest that
mechanisms on the circuit level that in principle could contribute
to the cognitive symptoms of schizophrenia already emerge
during prenatal development. In these mice, the selective upre-
gulation of D2 receptors in the striatum during development
leads to prefrontal-dependent cognitive deficits that cannot be
reversed by switching off the additional receptors in the adult
animal (Bach et al., 2008; Kellendonk et al., 2006).
Perhaps the most useful direction in which to take the animal
model approach is to study developmental mechanisms that
are extremely difficult to study in humans. Increasing our under-
standing of the changes in early development that result in
cognitive dysfunctions in adulthood would be a major step
forward. In mouse genetic models, we can perturb individual592 Neuron 65, March 11, 2010 ª2010 Elsevier Inc.molecules at any time point and look at the effect at anytime
point after. For example, in the striatal D2R overexpression
model, it is possible to quantify the neuronal projections in the
corticostriatal pathway using quantitative tracing techniques.
Such experiments, combined with immunohistochemistry, may
identify specific cell types and molecular markers involved in
any circuit abnormalities, and the relevance to schizophrenia of
such markers may be investigated by studying them in post
mortem tissue. Other novel mouse models that could be infor-
mative might include those that express cell-type-specific, easily
imaged markers, which would allow for the monitoring of cortico-
striatal projections as they develop. Such marker mice could be
subjected to the numerous pre-, peri-, or postnatal alterations,
including environmental insults that have been determined to
influence risk for schizophrenia, and one could then see when
and how such perturbations affect development of the tagged
circuit(s). Separate cohorts of mice that have not been sacrificed
for imaging could be allowed to develop and their adult cognitive
functions measured. By using different developmental insults
and inducing them at different time points in development, one
presumes that subtly different anatomical phenotypes will
ensue. A systematic comparison of the anatomical and cognitive
defects might allow one to make more detailed inferences about
the relative importance of specific pathways on specific cogni-
tive functions. By combining such studies with quantitative
assays of gene or protein expression, specifically in the tagged
cells, new candidate molecules may be identified, which one
could study in post mortem tissue to determine if similar changes
in expression occur in the brains of patients with schizophrenia.
One limitation of the approach is that some of the expression
changes identified may occur only during development and
therefore be undetectable in post mortem studies.
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We begin our conclusion with an open disclaimer. To focus
attention on the striatum, a relatively neglected area in schizo-
phrenia research, the discussion presented here focuses on
a specific hypothesis. Thus, this perspective is not aimed to be
a comprehensive review of the entire literature of schizophrenia
research but rather aimed to bring more attention to a possible
role of the striatum in schizophrenia. While there is solid evidence
for the involvement of the striatum, the vast majority of studies
so far have focused on the prefrontal cortex and hippocampus.
Indeed, we have not described important studies on the involve-
ment of the temporal lobe (Harrison, 2004; Seidman et al., 2003).
For example, hippocampal volume, which may be genetically
determined, has been found to be reduced already at onset of
schizophrenia and continues to decrease in volume as the
disease progresses. Altered function of the hippocampus could
be responsible for some of the cognitive deficits in patients with
schizophrenia, such as deficits in explicit memory. Moreover,
animal models suggest that hippocampal hyperactivity induces
subcortical dopaminergic hyperfunction. We have deliberately
not included these studies in this perspective.
The ultimate goal of understanding the biological basis for
the cognitive symptoms of schizophrenia is threefold. First and
foremost is the development of treatments that will ameliorate
these symptoms and thereby help patients with schizophrenia
to live a more functional life in society. Based on the data
reviewed here, we suggest that treatment strategies should not
overlook the striatum and any compensatory changes it may
induce in the prefrontal cortex as an important structure involved
in the generation of cognitive symptoms. Second, insights into
the biology of schizophrenia should give us insights into the
biology of human mental processes in general: into the sense
of self, into volition, and short-term memory.
The findings in mice raised a third consideration. They illus-
trate that mice can teach one a great deal about possible mech-
anism underlying the pathogenesis of schizophrenia. They show
that these mechanisms may already have been induced during
development and therefore may not be reversible at late
adolescence or early adulthood, when schizophrenia usually
precipitates. Medications given at the time of diagnosis must
therefore be directed against the compensatory changes that
have been induced by developmental alterations rather than
the specific, as yet unknown, underlying etiologic factors. One
limitation is, of course, that a specific pharmacological com-
pound may ameliorate a dysfunction in one structure, e.g., the
striatum, but at the same time may have detrimental effects in
other areas of the brain, such as cortex or thalamus. Treatment
strategies should therefore take advantage of differences in
dopamine signaling that may occur in different anatomical struc-
tures or pathways in the brain. Dopamine receptor heterodimer
complex formation, the phosphorylation or subcellular localiza-
tion of receptors, or the recruitment of downstream signaling
cascades may be distinct in different pathways or cell types in
the brain. One example of this strategy is the selective inhibitor
of the phosphodiesterase PDE10A, which targets the striatum
because PDE10A is predominantly expressed in the putamen
and caudate nucleus, exclusively in medium spiny neurons (Xie
et al., 2006). Pharmacological PDE10A inhibition has beenshown to be efficacious in preclinical models of the positive,
negative, and cognitive symptoms of schizophrenia (Grauer
et al., 2009), and one PDE10A inhibitor is currently undergoing
clinical trial. A recent comprehensive review of the potential of
PDE10A inhibitors has recently been published (Chappie et al.,
2009). Forty years after the dopamine hypothesis of schizo-
phrenia was first proposed, we are now in a position to benefit
from a substantial investment in understanding the different
dopamine pathways in molecular terms, in the healthy and
diseased brain.
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